Access the full text.
Sign up today, get DeepDyve free for 14 days.
C. Vorilhon, C. Chenaf, A. Mulliez, B. Pereira, G. Clerfond, N. Authier, F. Jean, P. Motreff, B. Citron, A. Eschalier, J. Lusson, R. Eschalier (2014)
Heart failure prognosis and management in over-80-year-old patients: data from a French national observational retrospective cohortEuropean Journal of Clinical Pharmacology, 71
(2014)
Prévalence du diabète traité pharmacologiquement et disparités territoriales en France en 2012
B. Fautrel, G. Cukierman, J. Joubert, C. Laurendeau, J. Gourmelen, F. Fagnani (2016)
Characteristics and management of rheumatoid arthritis in France: Analysis of a representative French national claims database resulting in an estimated prevalence of 0.35.Joint, bone, spine : revue du rhumatisme, 83 4
C. Roudier, N. Poutignat, A. Fagot-Campagna, A. Weill, A. Rudnichi, Nicolas, Thammavong, A. Fontbonne, B. Detournay (2009)
Prise en charge des personnes diabétiques de type 2 en France en 2007 et tendances par rapport à 2001
P Tuppin, L Roquefeuil, A Weill, P Ricordeau, Y Merlière (2010)
French national health insurance information system and the permanent beneficiaries sampleRev Epidemiol Santé Publique., 54
(2017)
Prévalence et incidence du diabète
(2010)
World Health Organization. International classification of diseases 10th revision
G. Lagasnerie, A. Aguade, P. Denis, A. Fagot-Campagna, C. Gastaldi-Ménager (2017)
The economic burden of diabetes to French national health insurance: a new cost-of-illness method based on a combined medicalized and incremental approachThe European Journal of Health Economics, 19
(2014)
Etude des algorithmes de définition de pathologies dans le système national d’information inter-régimes de l’assurance maladie (SNIIRAM)
(2012)
Prévalence du diabète traité pharmacologiquement et disparités territoriales en France en
(2011)
méthodologique
Rhys Williams (2016)
Estimating the national and global costs of diabetes.Diabetes research and clinical practice, 119
C. Marant, S. Fosse, I. Romon, A. Weill, D. Simon, M. Varroud-Vial, M. Malinsky, A. Fagot-Campagna (2006)
Quelle prise en charge de l'hypertension dans le diabète de type 2 ? Données d'ENTRED : (Échantillon national témoin représentatif des personnes diabétiques)Archives Des Maladies Du Coeur Et Des Vaisseaux, 99
(2013)
Economic costs of diabetes in USA in 2012
B. Fautrel, G. Cukierman, J. Joubert, C. Laurendeau, J. Gourmelen, F. Fagnani (2016)
Healthcare service utilisation costs attributable to rheumatoid arthritis in France: Analysis of a representative national claims database.Joint, bone, spine : revue du rhumatisme, 83 1
D. Simon, J. Dallongeville, B. Charbonnel, I. Bureau, B. Detournay, S. Leproust, L. Lévy-Bachelot, J. Gourmelen (2015)
Patterns of Pharmacological Treatment in Type 2 Diabetes in France in 2013.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 18 7
(2001)
Coût des soins remboursés par l’Assurance maladie aux personnes traitées pour diabète : Etudes Entred
L Mandereau-Bruno (2014)
493Bull Epidémiol Hebd., 30–31
D. Nathan (2009)
Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement of the American Diabetes Association and the European Association for the Study of DiabetesDiabetes Care, 32
Guide méthodologique . Choix méthodologiques pour l ’ évaluation économique à la HAS
B. Detournay, S. Halimi, J. Robert, C. Deschaseaux, S. Dejager (2015)
Hypoglycemia hospitalization frequency in patients with type 2 diabetes mellitus: a comparison of dipeptidyl peptidase 4 inhibitors and insulin secretagogues using the French health insurance databaseVascular Health and Risk Management, 11
(2010)
International classification of diseases 10th revision
(2013)
Consommation de soins et biens médicaux
S. Inzucchi, R. Bergenstal, J. Buse, M. Diamant, E. Ferrannini, M. Nauck, A. Peters, A. Tsapas, R. Wender, D. Matthews (2015)
Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of DiabetesDiabetologia, 58
S. Inzucchi, R. Bergenstal, J. Buse, M. Diamant, E. Ferrannini, M. Nauck, A. Peters, A. Tsapas, R. Wender, D. Matthews (2014)
Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of DiabetesDiabetes Care, 38
K. Tsilidis, John Kasimis, D. Lopez, E. Ntzani, J. Ioannidis (2015)
Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studiesBMJ : British Medical Journal, 350
(2007)
Caractéristiques, état de santé, prise en charge et poids économique des personnes diabétiques
P. Tuppin, L. Roquefeuil, Alain Weill, P. Ricordeau, Y. Merlière (2010)
French national health insurance information system and the permanent beneficiaries sample.Revue d'epidemiologie et de sante publique, 58 4
Ping Zhang, Xinzhi Zhang, Jonathan Brown, D. Vistisen, R. Sicree, J. Shaw, G. Nichols (2010)
Economic impact of Diabetes
F. Jones (1978)
International Classification of DiseasesGut, 19
P. Ricci, M. Chantry, B. Detournay, N. Poutignat, O. Kusnik-Joinville, V. Raimond, N. Thammavong, A. Weill
Coûts des soins remboursés par l ’ Assurance maladie aux personnes traitées pour diabète : Études Entred 2001 et 2007
(2001)
Prise en charge des personnes diabétiques de type 2 en France en 2007 et tendances par rapport à
Bruno Detournay, Dominique Simon, P. Guillausseau, D. Joly, Bruno Vergès, C. Attali, O. Clément, Y. Briand, O. Delaitre (2012)
Chronic kidney disease in type 2 diabetes patients in France: prevalence, influence of glycaemic control and implications for the pharmacological management of diabetes.Diabetes & metabolism, 38 2
(2016)
Direction de la recherche, des études, de l'évaluation et des statistiques. Les dépenses de santé en 2015. Résultats des comptes de la santé
S. Inzucchi, R. Bergenstal, J. Buse, M. Diamant, E. Ferrannini, M. Nauck, A. Peters, A. Tsapas, R. Wender, David Matthews, David Matthews, David Matthews (2013)
Erratum to: Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)Diabetologia, 56
Julie Dupouy, J. Fournier, Emilie Jouanjus, A. Palmaro, Jean-Christophe Poutrain, S. Oustric, M. Lapeyre-Mestre (2014)
Baclofen for alcohol dependence in France: Incidence of treated patients and prescription patterns—A cohort studyEuropean Neuropsychopharmacology, 24
(2015)
Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes
Melissa Aldridge, A. Kelley (2015)
The Myth Regarding the High Cost of End-of-Life Care.American journal of public health, 105 12
(2014)
Caisse Nationale de l'Assurance Maladie des Travailleurs Salariés. Rapport au ministre chargé de la Sécurité sociale et au Parlement sur l'évolution des charges et des produits de l'Assurance Maladie
PharmacoEconomics Open (2018) 2:209–219 https://doi.org/10.1007/s41669-017-0050-3 OR IGINAL RESEARCH ARTIC L E Direct Medical Costs of Type 2 Diabetes in France: An Insurance Claims Database Analysis 1 2 3 4 • • • • Bernard Charbonnel Dominique Simon Jean Dallongeville Isabelle Bureau 5 5 6 4 • • • Sylvie Dejager Laurie Levy-Bachelot Julie Gourmelen Bruno Detournay Published online: 7 August 2017 The Author(s) 2017. This article is an open access publication Abstract 12.5; 53.9% male) matched with a control group of 76,406 Objectives Our objects was to estimate the direct health- individuals without diabetes. Overall per patient per year care costs of type 2 diabetes mellitus (T2DM) in France in medical expenditures were €6506 ± 10,106 in the T2DM 2013. group as compared with €3668 ± 6954 in the control group. Methods Data were drawn from a random sample of The cost difference between the two groups was €2838 per &600,000 patients registered in the French national health patient per year, mainly due to hospitalizations, medication and insurances database, which covers 90% of the French nursing care costs. Total per capita annual costs were lowest for population. An algorithm was used to select patients with patients receiving metformin monotherapy
PharmacoEconomics - Open – Springer Journals
Published: Aug 7, 2017
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.